LGMC Conducting Research on Bronchoscopy Patients


Lafayette General Medical Center (LGMC) is seeking men and women at least 18 years of age or older who are scheduled to undergo a bronchoscopy to participate in a clinical trial.

This study will evaluate the effectiveness of a drug, called remimazolam, in inducing and maintaining suitable sedation levels for patients undergoing a bronchoscopy. Intensivist Brad Broussard, M.D., will be the chief investigator on this study.
This is a Phase III clinical trial. Drugs that successfully pass Phase III are usually approved for use in the general population by the FDA.

Lafayette General Medical Center participates in clinical trials to help improve patient care and disease prevention. Clinical trials offer several benefits, such as access to newer treatments and drugs that might not otherwise be available. Trials also help expand knowledge about the best ways to treat certain conditions. 

Research staff at LGMC will instruct patients on potential risks and benefits of participating in this clinical trial. The staff will then monitor and assess the progress of the trial.

When patients participate in a clinical trial, they are not only advancing medical technology, they are providing a valuable benefit to future generations. The goal of clinical trials at any Lafayette General Health facility is to support the patient-centered approach to health care.

For more information on this and other clinical trials available at Lafayette General Medical Center, call (337) 289-8658.

Back to News Listing